M&T Bank Corp Takes $572,000 Position in Stevanato Group S.p.A. (NYSE:STVN)

M&T Bank Corp bought a new position in Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,278 shares of the company's stock, valued at approximately $572,000.

Other institutional investors also recently bought and sold shares of the company. Zions Bancorporation N.A. acquired a new stake in shares of Stevanato Group during the 3rd quarter valued at about $1,049,000. Sivik Global Healthcare LLC purchased a new position in shares of Stevanato Group during the 3rd quarter worth $2,800,000. King Wealth Management Group increased its position in shares of Stevanato Group by 30.2% during the third quarter. King Wealth Management Group now owns 94,800 shares of the company's stock valued at $1,896,000 after acquiring an additional 22,000 shares during the last quarter. Royce & Associates LP raised its stake in shares of Stevanato Group by 45.8% in the 3rd quarter. Royce & Associates LP now owns 343,159 shares of the company's stock valued at $6,863,000 after acquiring an additional 107,869 shares during the period. Finally, Natixis Advisors LLC lifted its holdings in shares of Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company's stock worth $1,027,000 after acquiring an additional 8,669 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Bank of America boosted their target price on Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, December 13th. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Morgan Stanley reiterated an "equal weight" rating and set a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Wolfe Research started coverage on shares of Stevanato Group in a research note on Friday, December 13th. They issued an "outperform" rating and a $28.00 price objective for the company. Finally, UBS Group cut their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Stevanato Group presently has an average rating of "Moderate Buy" and a consensus target price of €27.75 ($30.16).

Remove Ads

Stevanato Group Stock Down 1.5 %

Shares of Stevanato Group stock traded down €0.30 ($0.33) on Thursday, reaching €19.82 ($21.54). 529,473 shares of the company were exchanged, compared to its average volume of 356,665. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a 1-year low of €16.56 ($18.00) and a 1-year high of €33.49 ($36.40). The company has a market cap of $6.00 billion, a P/E ratio of 42.17, a price-to-earnings-growth ratio of 7.18 and a beta of 0.60. The stock's 50 day moving average price is €21.30 and its 200-day moving average price is €20.58.

Stevanato Group (NYSE:STVN - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The business had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. As a group, equities analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.